Fenofibrate and Dark Urine: Risk of Rhabdomyolysis
Yes, fenofibrate can cause rhabdomyolysis, which produces dark urine (myoglobinuria), and this patient's presentation of abdominal pain warrants immediate evaluation for this potentially life-threatening complication.
Understanding the Link Between Fenofibrate and Rhabdomyolysis
Fenofibrate, while generally well-tolerated, carries a recognized risk of myopathy and rhabdomyolysis that can lead to dark urine from myoglobinuria. The FDA drug label explicitly warns that myopathy and rhabdomyolysis have been reported in patients taking fenofibrate, with risks particularly increased in elderly patients and those with diabetes, renal failure, or hypothyroidism 1. However, it's important to note that the patient describes clear urine, not dark urine, which makes active rhabdomyolysis less likely at this moment but does not eliminate the concern.
Key Risk Factors Present
The combination of abdominal pain in a patient on fenofibrate should raise immediate concern for several reasons:
- Fenofibrate monotherapy alone can cause rhabdomyolysis, even without concurrent statin use, though this is rare 2, 3, 4
- Renal impairment significantly increases risk: The ACC/AHA guidelines mandate that renal status be evaluated before fenofibrate initiation, within 3 months after initiation, and every 6 months thereafter, as fenofibrate can reversibly increase serum creatinine levels 5
- Abdominal pain is a warning symptom: The FDA label specifically instructs patients to inform their physician of onset of abdominal pain as a potential adverse effect 1
Clinical Evaluation Algorithm
Immediate Assessment Required
Check the following laboratory values urgently:
- Creatine kinase (CK): Severe myositis is characterized by CK levels generally greater than 10 times the upper limit of normal 5
- Serum creatinine and eGFR: Fenofibrate should be discontinued if eGFR decreases persistently to <30 mL/min per 1.73 m² 5
- Urinalysis for myoglobin: Dark urine from myoglobinuria indicates rhabdomyolysis with risk of acute renal failure 2, 3, 4
- Hepatic transaminases (ALT, AST): Elevated liver enzymes can occur with fenofibrate 5
- Serum electrolytes and renal function: To assess for acute kidney injury
Additional Considerations
The abdominal pain could represent:
- Cholelithiasis: Fenofibrate increases cholesterol excretion into bile, leading to increased risk of gallstones 1. If cholelithiasis is suspected, gallbladder studies are indicated 5
- Pancreatitis: Though fenofibrate is used to prevent pancreatitis in severe hypertriglyceridemia, paradoxical pancreatitis has been reported 5
- Early myopathy: Muscle symptoms may present as non-specific complaints before CK elevation becomes dramatic 5
Risk Stratification and Incidence
The actual incidence of rhabdomyolysis with fenofibrate monotherapy is extremely low. In a large retrospective study of over 1 million patients, the incidence rate of hospitalized rhabdomyolysis with statin monotherapy ranged from 0.00 to 3.34 per 100,000 person-years 6. Fenofibrate monotherapy carries similar low risk, but the risk increases substantially when combined with statins (adjusted IRR 3.26 for fenofibrate-statin vs statin alone) 6.
Case reports demonstrate that rhabdomyolysis from fenofibrate monotherapy typically occurs in patients with predisposing factors:
- Chronic renal failure or nephrotic syndrome 3
- Diabetes mellitus 4
- Hypoalbuminemia 3
- Inadequate dose adjustment for renal function 3
Management Recommendations
If Rhabdomyolysis is Confirmed (CK >10x ULN with symptoms):
Immediately discontinue fenofibrate 2, 3, 4, 7
Initiate aggressive treatment:
- Intravenous fluid resuscitation 2, 3, 4, 7
- Urinary alkalization 2, 3, 4
- Mannitol diuresis if needed 7
- Monitor for acute renal failure requiring hemodialysis 7
If Initial Workup is Negative but Symptoms Persist:
- Continue monitoring: The ACC/AHA guidelines recommend monitoring CK, ALT, and AST every 3 to 6 months during fibrate therapy 5
- Evaluate for alternative causes of abdominal pain
- Consider dose reduction if mild CK elevation without severe symptoms
- Reassess renal function: Fenofibrate dose should not exceed 54 mg/day if eGFR is between 30-59 mL/min per 1.73 m² 5
Critical Pitfalls to Avoid
Do not dismiss muscle symptoms or abdominal pain in patients on fenofibrate, even if they seem non-specific. The ACC/AHA guidelines note that in placebo-controlled trials, muscle complaints occur in about 5% of patients on both placebo and active drug, but temporal association with fenofibrate therapy may still implicate the drug 5.
Do not restart fenofibrate without careful consideration if rhabdomyolysis is confirmed. The risk-benefit ratio must be reassessed 5.
Do not overlook renal function monitoring. The combination of fenofibrate with even mild renal impairment significantly increases toxicity risk 3, 8.
Bottom Line
While the patient currently reports clear urine (not dark), the presence of abdominal pain on fenofibrate mandates urgent evaluation for early rhabdomyolysis, cholelithiasis, and renal dysfunction. Dark urine from myoglobinuria is a late and ominous sign of established rhabdomyolysis that can progress to acute renal failure requiring dialysis 2, 3, 4, 7. Early recognition and prompt discontinuation of fenofibrate, combined with aggressive supportive care, typically results in complete recovery 2, 3, 4.